Bile Acid-Mediated Control of Liver Triglycerides

被引:92
作者
Fuchs, Claudia [1 ]
Claudel, Thierry [1 ]
Trauner, Michael [1 ]
机构
[1] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Hans Popper Lab Mol Hepatol, A-1090 Vienna, Austria
关键词
farnesoid X receptor; TGR5; FGF15; 19; 21; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; glucose; FARNESOID-X-RECEPTOR; SMALL HETERODIMER PARTNER; SOLUTE TRANSPORTER-ALPHA; LOW-DENSITY-LIPOPROTEIN; NUCLEAR RECEPTOR; URSODEOXYCHOLIC ACID; NONALCOHOLIC STEATOHEPATITIS; GENE-EXPRESSION; INSULIN SENSITIVITY; BETA-KLOTHO;
D O I
10.1055/s-0033-1358520
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Bile acids (BAs) are steroidal molecules generated in the liver by cholesterol oxidation. Beside their well-established role in lipid absorption and cholesterol homeostasis, they function as signaling molecules and activate dedicated BA receptors such as the farnesoid X receptor (FXR) and the G-protein coupled receptor TGR5. Through activation of downstream signaling pathways of these key receptors, BAs regulate not only their own synthesis and enterohepatic circulation, but also impact on hepatic lipid, glucose, and energy homeostasis. Therefore, BA-regulated signaling pathways have emerged as attractive targets for understanding the regulation of hepatic triglyceride metabolism in health and disease and treating fatty liver disease and associated metabolic disorders.
引用
收藏
页码:330 / 342
页数:13
相关论文
共 165 条
[1]
The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-γ and Interfering with the Wnt/β-Catenin Pathways [J].
Abdelkarim, Mouaadh ;
Caron, Sandrine ;
Duhem, Christian ;
Prawitt, Janne ;
Dumont, Julie ;
Lucas, Anthony ;
Bouchaert, Emmanuel ;
Briand, Olivier ;
Brozek, John ;
Kuipers, Folkert ;
Fievet, Catherine ;
Cariou, Bertrand ;
Staels, Bart .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (47) :36759-36767
[2]
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2 [J].
Abu-Elheiga, L ;
Matzuk, MM ;
Abo-Hashema, KAH ;
Wakil, SJ .
SCIENCE, 2001, 291 (5513) :2613-2616
[3]
Common Variants of ABCB4 and ABCB11 and Plasma Lipid Levels: A Study in Sib Pairs with Gallstones, and Controls [J].
Acalovschi, Monica ;
Tirziu, Simona ;
Chiorean, Erica ;
Krawczyk, Marcin ;
Gruenhage, Frank ;
Lammert, Frank .
LIPIDS, 2009, 44 (06) :521-526
[4]
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis [J].
Adorini, Luciano ;
Pruzanski, Mark ;
Shapiro, David .
DRUG DISCOVERY TODAY, 2012, 17 (17-18) :988-997
[5]
Genetic determinants of serum lipid levels in Chinese subjects: a population-based study in Shanghai, China [J].
Andreotti, Gabriella ;
Menashe, Idan ;
Chen, Jinbo ;
Chang, Shih-Chen ;
Rashid, Asif ;
Gao, Yu-Tang ;
Han, Tian-Quan ;
Sakoda, Lori C. ;
Chanock, Stephen ;
Rosenberg, Philip S. ;
Hsing, Ann W. .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2009, 24 (12) :763-774
[6]
STUDIES ON THE REGULATION OF HEPATIC CHOLESTEROL-METABOLISM IN HUMANS [J].
ANGELIN, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (04) :215-224
[7]
ANGELIN B, 1978, J LIPID RES, V19, P1017
[8]
Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[9]
Gut microbiota and non-alcoholic fatty liver disease: new insights [J].
Aron-Wisnewsky, J. ;
Gaborit, B. ;
Dutour, A. ;
Clement, K. .
CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) :338-348
[10]
Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002